Galapagos and Gilead Launch the Fifth New Trial for Filgotinib this Year

With the addition of uveitis, Galapagos and Gilead are raising to 10 the number of indications in filgotinib’s clinical pipeline.

Galapagos and Gilead clearly have big expectations for filgotinib. The small molecule is already in Phase III for rheumatoid arthritis, Crohn’s disease and ulcerative colitis. The team is now launching a new Phase II trial in non-infectious uveitis, which adds up to other four new Phase II trials that were launched earlier this year in Sjögren’s syndrome, ankylosing spondylitis, psoriatic arthritis, and lupus erythematosus.

Though these diseases are very different to each other, the trials are based in filgotinib’s ability to block JAK1, a protein involved in multiple inflammatory signaling pathways. This new indication will make the team step into ophthalmic diseases, where a number of biotechs are already developing their own approaches to treat uveitis. Among them are Elasmogen, developing small, shark-inspired antibodiesTxCell, working on a cell therapy; and Eyevensys, which is going after a virus-free gene therapy.

Image via D. Kucharski K. Kucharska / Shutterstock

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.